PuriCore plc (LON:PURI)‘s stock had its “corporate” rating reaffirmed by equities researchers at N+1 Singer in a research note issued on Tuesday.

PuriCore plc (LON:PURI) traded up 22.89% during mid-day trading on Tuesday, reaching GBX 25.50. The company’s stock had a trading volume of 231,686 shares. The firm has a 50 day moving average price of GBX 20.74 and a 200-day moving average price of GBX 22.73. The company’s market capitalization is GBX 12.78 million. PuriCore plc has a 1-year low of GBX 16.90 and a 1-year high of GBX 28.78.

PuriCore plc Company Profile

PuriCore Plc is a biopharmaceutical company engaged in leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company is also engaged in development of small molecule therapies in inflammatory diseases with application in dermatology, ophthalmology and rare diseases, and also for applicability across various other diseases.

Receive News & Ratings for PuriCore plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PuriCore plc and related companies with MarketBeat.com's FREE daily email newsletter.